AR031431A1 - Combinacion de agonistas de gaba e inhibidores de sorbitol-deshidrogenasa - Google Patents

Combinacion de agonistas de gaba e inhibidores de sorbitol-deshidrogenasa

Info

Publication number
AR031431A1
AR031431A1 ARP010105541A ARP010105541A AR031431A1 AR 031431 A1 AR031431 A1 AR 031431A1 AR P010105541 A ARP010105541 A AR P010105541A AR P010105541 A ARP010105541 A AR P010105541A AR 031431 A1 AR031431 A1 AR 031431A1
Authority
AR
Argentina
Prior art keywords
diabetic
prodrug
combinations
deshidrogenasa
sorbitol
Prior art date
Application number
ARP010105541A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR031431A1 publication Critical patent/AR031431A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente se refiere a composiciones farmacéuticas que comprenden combinaciones de un agonista de GABA, un profármaco del mismo o una sal farmacéuticamente aceptable de dicho agonista de GABA o dicho profármaco y un SDI, un profármaco del mismo o una sal farmacéuticamente aceptable de dicho SDI o dicho profármaco, estuches que contienen tales combinaciones y métodos para utilizar tales combinaciones en el tratamiento de mamíferos, incluidos los seres humanos, que padecen complicaciones de la diabetes tales como neuropatía diabética, nefropatía diabética, cardiomiopatía diabética, retinopatía diabética, microangiopatía diabética, macroangiopatía diabética, cataratas o ulceras de los pies.
ARP010105541A 2000-11-30 2001-11-28 Combinacion de agonistas de gaba e inhibidores de sorbitol-deshidrogenasa AR031431A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25006900P 2000-11-30 2000-11-30

Publications (1)

Publication Number Publication Date
AR031431A1 true AR031431A1 (es) 2003-09-24

Family

ID=22946187

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010105541A AR031431A1 (es) 2000-11-30 2001-11-28 Combinacion de agonistas de gaba e inhibidores de sorbitol-deshidrogenasa

Country Status (38)

Country Link
US (1) US6544998B2 (es)
EP (1) EP1337271B1 (es)
JP (1) JP2004514699A (es)
KR (1) KR20030059290A (es)
CN (1) CN1477975A (es)
AP (1) AP2001002360A0 (es)
AR (1) AR031431A1 (es)
AT (1) ATE281181T1 (es)
AU (1) AU2002215159A1 (es)
BG (1) BG107774A (es)
BR (1) BR0115783A (es)
CA (1) CA2430298A1 (es)
CR (1) CR6964A (es)
CZ (1) CZ20031399A3 (es)
DE (1) DE60106968T2 (es)
DO (1) DOP2001000289A (es)
EA (1) EA200300432A1 (es)
EC (1) ECSP034624A (es)
EE (1) EE200300248A (es)
ES (1) ES2230378T3 (es)
HR (1) HRP20030420A2 (es)
HU (1) HUP0302160A3 (es)
IL (1) IL155704A0 (es)
IS (1) IS6786A (es)
MA (1) MA26964A1 (es)
MX (1) MXPA03004870A (es)
NO (1) NO20032441L (es)
OA (1) OA12534A (es)
PA (1) PA8534101A1 (es)
PE (1) PE20020597A1 (es)
PL (1) PL365927A1 (es)
PT (1) PT1337271E (es)
SK (1) SK6192003A3 (es)
SV (1) SV2003000751A (es)
TN (1) TNSN01169A1 (es)
UY (1) UY27042A1 (es)
WO (1) WO2002043762A2 (es)
ZA (1) ZA200303381B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL189872B1 (pl) 1996-07-24 2005-10-31 Warner Lambert Co Zastosowanie izobutylogaby i jej pochodnych do wytwarzania leku do leczenia bólu
US6992109B1 (en) * 1999-04-08 2006-01-31 Segal Catherine A Method for the treatment of incontinence
US7022678B2 (en) * 2001-03-30 2006-04-04 Warner-Lambert Company Pregabalin lactose conjugates
OA12604A (en) * 2001-05-25 2006-06-08 Warner Lambert Co Liquid pharmaceutical composition.
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
KR20050036195A (ko) * 2003-10-15 2005-04-20 고재영 신규한 망막병증 치료제 조성물
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
US20050226927A1 (en) * 2004-04-02 2005-10-13 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist
KR20070020022A (ko) * 2004-04-02 2007-02-16 임팩스 라보라토리즈, 인코포레이티드 Ｇａｂａ 수용체 효능제에 대한 제어 방출 제형
US20050220873A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain a GABAB receptor agonist
GB0420831D0 (en) 2004-09-17 2004-10-20 Glaxo Group Ltd Novel compounds
MX2007010076A (es) 2005-02-17 2007-10-16 Astellas Pharma Inc Derivado de heterociclico-1-carboxilato que contiene nitrogeno no aromatico de piridilo.
GB0513553D0 (en) * 2005-07-01 2005-08-10 Fond D Amico Per La Ricerca Su Rab3a
EP2142529B1 (en) 2007-04-27 2013-12-25 Purdue Pharma LP Trpv1 antagonists and uses thereof
JP5452494B2 (ja) * 2007-10-09 2014-03-26 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンフォチアミンと１または２種以上の医薬活性剤とを含む神経因性の疼痛状態の処置のための医薬組成物
EP2116618A1 (en) 2008-05-09 2009-11-11 Agency for Science, Technology And Research Diagnosis and treatment of Kawasaki disease
JP5815552B2 (ja) 2009-12-08 2015-11-17 ケース ウェスタン リザーブ ユニバーシティＣａｓｅ Ｗｅｓｔｅｒｎｒｅｓｅｒｖｅ Ｕｎｉｖｅｒｓｉｔｙ 眼疾患を治療する化合物および方法
WO2012050907A2 (en) * 2010-09-28 2012-04-19 The Regents Of The University Of California Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes
RU2621708C2 (ru) 2011-06-22 2017-06-07 ПУРДЬЮ ФАРМА Эл. Пи. Антагонисты trpv1, включающие дигидроксигруппу в качестве заместителя, и их применение
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
CN114206349A (zh) 2019-04-17 2022-03-18 指南针探路者有限公司 治疗神经认知障碍、慢性疼痛及减轻炎症的方法
SG11202111822QA (en) * 2019-05-07 2021-11-29 Univ Miami Treatment and detection of inherited neuropathies and associated disorders

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2409754A (en) 1946-10-22 Method for obtaining hydantoins
CH449645A (de) 1963-07-09 1968-01-15 Ciba Geigy Verfahren zur Herstellung neuer Aminosäuren
CH427803A (de) 1963-12-06 1967-01-15 Geigy Ag J R Verfahren zur Herstellung eines neuen Isoxazolderivates
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US3960927A (en) 1975-03-18 1976-06-01 Richardson-Merrell Inc. Olefinic derivatives of amino acids
FR2319338A1 (fr) * 1975-08-01 1977-02-25 Synthelabo Nouveaux derives de a- phenyl benzylideniques des acides amines, leur preparation et les medicaments qui en contiennent
GR68380B (es) 1979-06-01 1981-12-28 Wellcome Found
FR2492258A1 (fr) * 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
DK288385D0 (da) 1985-06-26 1985-06-26 Novo Industri As Aminosyrederivater
US6197819B1 (en) 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
KR950703539A (ko) * 1992-09-28 1995-09-20 알렌 제이. 스피겔 당뇨병 합병증 치료용 치환된 피리미딘(substituted pyrimidines for control or diabetic complications)
AU3503300A (en) * 1999-02-24 2000-09-14 Regents Of The University Of California, The Gaba receptors mediate inhibition of t cell responses
WO2000059510A1 (en) * 1999-04-01 2000-10-12 Pfizer Products Inc. Aminopyrimidines as sorbitol dehydrogenase inhibitors
ATE264311T1 (de) * 1999-04-01 2004-04-15 Pfizer Prod Inc Verbindungen zur behandlung und vorsorge bei diabetes

Also Published As

Publication number Publication date
UY27042A1 (es) 2002-07-31
US6544998B2 (en) 2003-04-08
DOP2001000289A (es) 2003-02-15
CA2430298A1 (en) 2002-06-06
EP1337271A2 (en) 2003-08-27
AU2002215159A1 (en) 2002-06-11
BR0115783A (pt) 2003-09-16
CN1477975A (zh) 2004-02-25
EA200300432A1 (ru) 2003-10-30
ZA200303381B (en) 2004-04-30
CZ20031399A3 (cs) 2004-04-14
WO2002043762A3 (en) 2003-03-13
ECSP034624A (es) 2003-07-25
HUP0302160A3 (en) 2005-05-30
KR20030059290A (ko) 2003-07-07
EE200300248A (et) 2003-10-15
SK6192003A3 (en) 2004-07-07
MA26964A1 (fr) 2004-12-20
ES2230378T3 (es) 2005-05-01
PA8534101A1 (es) 2002-10-31
HUP0302160A2 (hu) 2003-11-28
DE60106968T2 (de) 2005-11-03
PL365927A1 (en) 2005-01-10
WO2002043762A2 (en) 2002-06-06
HRP20030420A2 (en) 2004-08-31
SV2003000751A (es) 2003-01-13
DE60106968D1 (de) 2004-12-09
IL155704A0 (en) 2003-11-23
NO20032441L (no) 2003-07-03
PE20020597A1 (es) 2002-07-08
EP1337271B1 (en) 2004-11-03
PT1337271E (pt) 2005-01-31
US20020091128A1 (en) 2002-07-11
NO20032441D0 (no) 2003-05-28
AP2001002360A0 (en) 2001-12-31
OA12534A (en) 2006-06-05
MXPA03004870A (es) 2003-08-19
JP2004514699A (ja) 2004-05-20
TNSN01169A1 (fr) 2005-11-10
BG107774A (en) 2004-01-30
CR6964A (es) 2004-02-02
ATE281181T1 (de) 2004-11-15
IS6786A (is) 2003-04-14

Similar Documents

Publication Publication Date Title
AR031431A1 (es) Combinacion de agonistas de gaba e inhibidores de sorbitol-deshidrogenasa
AR031432A1 (es) Combinacion de agonistas de gaba e inhibidores de aldosa-reductasa
AR067347A1 (es) Combinacion antihelmintica
GT200500173A (es) Compuestos de heteroaril- y fenilsulfamoilo sustituidos
ES2581331T3 (es) Inhibidor de la progresión de una enfermedad atribuida a una acumulación anormal de grasa hepática
ES2487496T3 (es) Agente para aliviar el síndrome metabólico
CL2022001583A1 (es) Derivados espiráncos sustituidos de cadena lineal
CL2008002227A1 (es) Compuestos derivados de 4-[(8r)-4-amino-5-oxo-7,8-dihidrorimido[5,4-f][1,4]oxazepin-6(5h)-il]fenilo sustituido; su composicion farmaceutica; y uso de los compuestos en el tratamiento de la diabetes de tipo 2, utiles particularmente para tratar la obesidad.
CR11418A (es) Trans-clomifeno para el sindrome metabolico
AR067903A1 (es) Metodo para tratar la depresion mediada por estres
CL2011000851A1 (es) Composicion farmaceutica que comprende al menos una insulina y al menos un agonista de glp-1; metodo de preparacion; su uso para tratar diabetes o prevenir la disfuncion de celulas beta pancreaticas; kit; y dispositivo.
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
CL2011001131A1 (es) Uso de una formulacion que sirve para preparar un medicamento para una inyeccion, que reduce al minimo la inflamacion en el sitio de la inyeccion de un anticuerpo, y donde la formulacion comprendeun anticuerpo 2h7 y variantes del anticuerpo y polivinilpirrolidona (pvp)
CL2008003576A1 (es) Compuestos derivados de amida del acido 6,7-dihidro-5h-imidazo[1,2-alfa]imidazol-3-carboxilico; composicion farmaceutica que los comprende; y usos en el tratamiento de una afeccion inflamatoria.
ES2552654T3 (es) Uso de LCAT para tratar la anemia y la disfunción de los glóbulos rojos
ES2582660T3 (es) Sidnoniminas - inhibidores específicos de la recaptación de la dopamina y su uso en el tratamiento de los trastornos relacionados con la dopamina
AR056517A1 (es) Composiciones y metodos farmaceuticos utilizando temozolomida y un inhibidor de la proteina quinasa
CL2008001477A1 (es) Composicion farmaceutica compuesta por la combinacion sinergica de un agente anticonvulsivante como gabapentina y un agente antiinflamatorio no esteroideo como meloxicam, los rangos de concentracion presentes para la gabapentina son 3 a 300 mg y de 0,1 a 30 mg para meloxicam; y uso para tratar el dolor neuropatico
AR033596A1 (es) Composicion farmaceutica para inyeccion intramuscular que contiene loxoprofeno
AR046213A1 (es) Forma de presentacion del naproxeno sodico
AR067351A1 (es) Combinacion de picotamida con nafronil
GT200500042A (es) Compuestos de heteroaril- y fenilsulfamoilo sustituidos
AR048355A1 (es) Asociacion entre un compuesto heterociclico y un agente antioxidante y las composiciones farmaceuticas que los contienen
AR061046A1 (es) Mirtazapina para el tratamiento del dolor neuropatico

Legal Events

Date Code Title Description
FB Suspension of granting procedure